ArticleMolecular cancer research : MCR2021
HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- P95-HER2 promotes metastatic progression by biasing MRTFA dependent signaling.bioRxiv : the preprint server for biology · 2026Article
- Intercellular signaling reinforces single-cell level phenotypic transitions and facilitates robust re-equilibrium of heterogeneous cancer cell populations.Cell communication and signaling : CCS · 2025Article
- CoSiDeX: A hyperspectral fluorescent protein resource for highly multiplexed imaging.bioRxiv : the preprint server for biology · 2025Article
- Precision preclinical modeling to advance cancer treatment.Journal of the National Cancer Institute · 2025Review
- Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers.Gynecologic oncology · 2025Review
- Nonlinear progression during the occult transition establishes cancer lethality.Disease models & mechanisms · 2025Article
- A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.Neuro-oncology · 2024Article
- Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent "NoGlow" Mice.Cancer research communications · 2024Article
- Molecular Characterization and Landscape of Breast cancer Models from a multi-omics Perspective.Journal of mammary gland biology and neoplasia · 2023Review
- Precancerous Lesions of the Head and Neck Region and Their Stromal Aberrations: Piecemeal Data.Cancers · 2023Review
- Veterinary Management of Harderian Gland Tumors in Cancer Rainbow (crainbow) HER2-Positive Mice.Comparative medicine · 2022Article
- How Lineage Tracing Studies Can Unveil Tumor Heterogeneity in Breast Cancer.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Joshua D Ginzel *Department of Cell Biology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-5635-7314
Chaitanya R Acharya *Department of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-7149-1749
Veronica Lubkov *Department of Cell Biology, Duke University Medical Center, Durham, North Carolina.
Hidetoshi MoriDepartment of Pathology and Laboratory Medicine and The Center for Immunology and Infectious Disease, University of California-Davis, Davis, California.
Peter G BooneDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina.
Lauren K RochelleDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-0669-1362
Wendy L RobertsDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina.
Jeffrey I EverittDepartment of Pathology, Duke University Medical School, Durham, North Carolina.ORCID 0000-0003-0273-6284
Zachary C HartmanDepartment of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-6549-8207
Erika J CrosbyDepartment of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-4872-6711
Lawrence S BarakDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-9170-2141
Marc G CaronDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina.
Jane Q ChenDepartment of Pathology and Laboratory Medicine and The Center for Immunology and Infectious Disease, University of California-Davis, Davis, California.
Neil E HubbardDepartment of Pathology and Laboratory Medicine and The Center for Immunology and Infectious Disease, University of California-Davis, Davis, California.
Robert D Cardiff *Department of Pathology and Laboratory Medicine and The Center for Immunology and Infectious Disease, University of California-Davis, Davis, California.ORCID 0000-0003-3088-8816
Alexander D Borowsky *Department of Pathology and Laboratory Medicine and The Center for Immunology and Infectious Disease, University of California-Davis, Davis, California.
H Kim Lyerly *Department of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-0063-4770
Joshua C Snyder *Department of Cell Biology, Duke University Medical Center, Durham, North Carolina. joshua.snyder@duke.edu.ORCID 0000-0002-9787-3371
Duke University · USUniversity of California, Davis · US
Funding
Viral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9MTraining Program in Developmental & Stem Cell BiologyT32HD040372 · NICHD · DUKE UNIVERSITY · PI Terry H Lechler · 2001 to 2026
$8.9MClinical Oncology Research Career Development ProgramK12CA100639 · NCI · DUKE UNIVERSITY · PI LYERLY, HERBERT KIM · 2004 to 2013
$8.0MCoordination Center for Open Collaboration in Systems BiologyU24CA209923 · NCI · SAGE BIONETWORKS · PI BLETZ, JULIE ANN · 2016 to 2021
$7.4MElucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancersU01CA196406 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOROWSKY, ALEXANDER D, ESSERMAN, LAURA J · 2015 to 2020
$5.8MEnabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancersR01CA238217 · NCI · DUKE UNIVERSITY · PI HARTMAN, ZACHARY CONRAD · 2020 to 2024
$2.4MVisualizing tumor heterogeneity in an immune intact and autochthonous mouse model of breast cancerR01CA255372 · NCI · DUKE UNIVERSITY · PI SNYDER, JOSHUA CLAIR · 2021 to 2025
$2.3MA Cancer Rainbow Mouse for Simultaneous Assessment of Multiple OncogenesR33CA191198 · NCI · DUKE UNIVERSITY · PI CARON, MARC G. · 2015 to 2017
$1.2MSupplemental Funds for K22 Establishing the molecular and cellular mechanisms of Lgr5 signaling for controlling cancer stem cell behaviorK22CA212058 · NCI · DUKE UNIVERSITY · PI SNYDER, JOSHUA CLAIR · 2017 to 2020
$622kA Cancer Rainbow Mouse for the Simultaneous Assessment of Multiple OncogenesR21CA173245 · NCI · DUKE UNIVERSITY · PI CARON, MARC G. · 2012 to 2013
$476kNCI NIH HHS K12 CA100639NCI NIH HHS K22 CA212058NCI NIH HHS R01 CA238217NCI NIH HHS R01 CA255372NCI NIH HHS R21 CA173245NCI NIH HHS R33 CA191198NCI NIH HHS T32 CA009111NCI NIH HHS U01 CA196406NCI NIH HHS U24 CA209923NICHD NIH HHS T32 HD040372
Abstract
HER2-positive breast cancers are among the most heterogeneous breast cancer subtypes. The early amplification of HER2 and its known oncogenic isoforms provide a plausible mechanism in which distinct programs of tumor heterogeneity could be traced to the initial oncogenic event. Here a Cancer rainbow mouse simultaneously expressing fluorescently barcoded wildtype (
Indexed as
AnimalsBreast NeoplasmsCarcinogenesisErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticMiceMice, KnockoutProtein IsoformsTumor MicroenvironmentErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesProtein Isoforms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.